Patent classifications
C07D473/06
SUBSTITUTED XANTHINE DERIVATIVES
The present invention relates to compounds of formula (I) a process for their manufacture, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment of conditions having an association with TRPC5 containing ion channels. R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 have meanings given in the description.
ADENOSINE RECEPTOR ANTAGONISTS AND USES THEREOF
Disclosed herein are compounds, compositions, formulations, and methods for modulating the A.sub.2B adenosine receptor.
ADENOSINE RECEPTOR ANTAGONISTS AND USES THEREOF
Disclosed herein are compounds, compositions, formulations, and methods for modulating the A.sub.2B adenosine receptor.
Substituted Xanthines and Methods of Use Thereof
Compounds, compositions and methods are described for inhibiting the TRPC5 ion channel and disorders related to TRPC5.
Substituted Xanthines and Methods of Use Thereof
Compounds, compositions and methods are described for inhibiting the TRPC5 ion channel and disorders related to TRPC5.
INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL
The present invention relates to pharmaceutical compounds of the Formula (I), or a pharmaceutically acceptable salt or composition thereof, and methods of their use for the treatment of pain, respiratory conditions, as well as inhibiting the Transient Receptor Potential A1 ion channel (TRPA1).
Purine inhibitors of human phosphatidylinositol 3-kinase delta
- Abdelghani Abe Achab ,
- Michael D. Altman ,
- Yongqi Deng ,
- Timothy Guzi ,
- Solomon Kattar ,
- Jason D. Katz ,
- Joey L. Methot ,
- Hua Zhou ,
- Meredeth McGowan ,
- Matthew P. Christopher ,
- Yudith Garcia ,
- Neville John Anthony ,
- Francesc Xavier Fradera Llinas ,
- Kin Chiu Fong ,
- Xiansheng Leng ,
- Changwei Mu ,
- Sixing Zhang ,
- Rong Zhang
The instant invention provides compounds of formula I which are PI3K-delta inhibitors, and as such are useful for the treatment of PI3K-delta-mediated diseases such as inflammation, asthma, COPD and cancer. ##STR00001##
Purine inhibitors of human phosphatidylinositol 3-kinase delta
- Abdelghani Abe Achab ,
- Michael D. Altman ,
- Yongqi Deng ,
- Timothy Guzi ,
- Solomon Kattar ,
- Jason D. Katz ,
- Joey L. Methot ,
- Hua Zhou ,
- Meredeth McGowan ,
- Matthew P. Christopher ,
- Yudith Garcia ,
- Neville John Anthony ,
- Francesc Xavier Fradera Llinas ,
- Kin Chiu Fong ,
- Xiansheng Leng ,
- Changwei Mu ,
- Sixing Zhang ,
- Rong Zhang
The instant invention provides compounds of formula I which are PI3K-delta inhibitors, and as such are useful for the treatment of PI3K-delta-mediated diseases such as inflammation, asthma, COPD and cancer. ##STR00001##
Substituted xanthines and methods of use thereof
Compounds, compositions and methods are described for inhibiting the TRPC5 ion channel and disorders related to TRPC5.
Substituted xanthines and methods of use thereof
Compounds, compositions and methods are described for inhibiting the TRPC5 ion channel and disorders related to TRPC5.